



Durvalumab

Chemical Properties

CAS No.: 1428935-60-7

Formula: N/A
Molecular Weight: N/A
Appearance: N/A

Storage: 0-4°C for short term (days to weeks), or -20°C for long term (months).

Biological Description

Description	Durvalumab is an anti-PD-L1 monoclonal antibody, humanized. Durvalumab completely blocked the binding of PD-L1 to PD-1 and CD80, and the IC50s were 0.1 and 0.04 nM, respectively.
Targets(IC ₅₀)	PD-L1/PD-1: 0.1 nM PD-L1/CD80: 0.04 nM
In vivo	Durvalumab inhibits tumor growth in a mouse xenograft model of human melanoma (A375) and pancreatic (HPAC) tumor cell lines through a T-cell-mediated mechanism. The tumor growth inhibition of HPAC cells was 74% and that of A375 cells was 77%. Durvalumab had no effect on the growth of the A375 xenograft tumor in the absence of T cells.

Solubility Information

Solubility	< 1 mg/ml refers to the product slightly soluble or insoluble	
------------	---	--

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. The storage conditions and period of the stock solution: - 80 °C for 6 months; - 20 °C for 1 month. Please use it as soon as possible.

Reference

- 1. Faiena I, et al. Durvalumab: an investigational anti-PD-L1 monoclonal antibody for the treatment of urothelial carcinoma. Drug Des Devel Ther. 2018 Jan 23;12:209-215.
- 2. Stewart R, et al. Identification and Characterization of MEDI4736, an Antagonistic Anti-PD-L1 Monoclonal Antibody. Cancer Immunol Res. 2015 Sep;3(9):1052-62.

Page 1 of 2 www.targetmol.com

Inhibitors · Natural Compounds · Compound Libraries

This product is for Research Use Only \cdot Not for Human or Veterinary or Therapeutic Use.

Tel:781-999-4286

E-mail:info@targetmol.com

Address:36 Washington Street, Wellesley Hills, MA 02481

Page 2 of 2 www.targetmol.com